Welcome
We manage the Government's investment in health research. Our vision is to improve the health and quality of life of all New Zealanders.
Funding Opportunities
The HRC allocates funding through an annual funding round for researcher initiated projects, Requests for Proposals, and a range of career development awards.
About Us
We invest in a broad range of research on issues important to New Zealand, and support the development of health research careers. Our mission is 'benefiting New Zealand through health research'.
News and Publications
We produce a wide range of publications and documents, which provide information about funding opportunities, research outcomes and HRC-related news.
Ethics and Regulatory
We help ensure all research involving human participants is based on good science, meets ethical standards and complies with best practice.
Contact Us
If you have any questions about the HRC or would like to know more about how our funding process works, please drop us a line.
Gene Technology Advisory Committee
Professor Catherine Day
Project
Professor
Catherine
Day
University of Otago, Dunedin
Integration of inflammatory signalling by TNF receptor associated factors
$1,185,038
36 months
Lay summary
Initiation and resolution of inflammation is essential for cellular homeostasis, and aberrations are associated with a range of diseases. Regulation of inflammation relies on signals transmitted from receptors on the surface of cells to the nucleus. Often, several cell surface receptors act in combination to elicit a particular inflammatory response. TNF receptor associated factors (TRAFs) are a key family of proteins that recognise many different activated receptors, and translate their signals into an appropriate response. Improper TRAF signalling is implicated in cancer, chronic inflammatory disorders and immune deficiency. The proposed project will investigate precisely how TRAF proteins function in combination with each other to reliably integrate inflammatory signals. This work will provide fundamental knowledge about the mechanisms of inflammatory signalling, identify possible molecular targets for cancer and chronic inflammation, and explain how existing therapies that target immune receptors control downstream signalling pathways might be used for maximum benefit.
Print